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Abstract
Background: Outcome measures for clinical trials in neuromuscular diseases are typically based on physical assessments
which are dependent on patient effort, combine the effort of different muscle groups, and may not be sensitive to
progression over short trial periods in slow-progressing diseases. We hypothesised that quantitative fat imaging by MRI
(Dixon technique) could provide more discriminating quantitative, patient-independent measurements of the progress of
muscle fat replacement within individual muscle groups.
Objective: To determine whether quantitative fat imaging could measure disease progression in a cohort of limb-girdle
muscular dystrophy 2I (LGMD2I) patients over a 12 month period.
Methods: 32 adult patients (17 male;15 female) from 4 European tertiary referral centres with the homozygous c.826C.A
mutation in the fukutin-related protein gene (FKRP) completed baseline and follow up measurements 12 months later.
Quantitative fat imaging was performed and muscle fat fraction change was compared with (i) muscle strength and
function assessed using standardized physical tests and (ii) standard T1-weighted MRI graded on a 6 point scale.
Results: There was a significant increase in muscle fat fraction in 9 of the 14 muscles analyzed using the quantitative MRI
technique from baseline to 12 months follow up. Changes were not seen in the conventional longitudinal physical
assessments or in qualitative scoring of the T1w images.
Conclusions: Quantitative muscle MRI, using the Dixon technique, could be used as an important longitudinal outcome
measure to assess muscle pathology and monitor therapeutic efficacy in patients with LGMD2I.
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Introduction
Limb-girdle muscular dystrophy 2I (LGMD2I) is an autosomal
recessive disease frequently caused by a homozygous founder
mutation (c.826C.A) in the fukutin-related protein gene (FKRP)
[1,2]. LGMD2I is one of the most common forms of LGMD in
northern Europe [3]. The disease is heterogeneous with age of
onset, rate of progression and degree of severity varying greatly.
Respiratory and cardiac complications are common, and can
occur independently from the skeletal muscle weakness [4,5,6,7].
As putative therapies for muscular dystrophies continue to be
developed, identification of objective and sensitive markers of
longitudinal change is important.
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Presently, measures based on physical function testing (such as
the 6 minute walk distance, time to rise from a chair, muscle force
measurements or composite scores) are used as primary end-points
in therapy trials. However, these measurements are dependent on
patient motivation, may be subject to learning effects and have
limited reproducibility, reducing their power to detect small
differences in clinical trials. These functional measures also
typically combine the efforts of several different muscle groups,
whereas it is known that muscle pathology can advance at
markedly different rates in different muscles.
Previous magnetic resonance imaging (MRI) research has
concentrated on small cross-sectional studies employing standard
T1-weighted imaging interpreted by radiological scoring and
reporting the patterns of muscle involvement in specific muscular
dystrophies [8,9,10,11,12]. However, qualitative scoring is subjec-
tive, typically limited to a scale of 4–6 grades, and hence masks
small changes in muscle pathology. The quantitative Dixon
technique allows fat fraction analysis [13], correcting for
inhomogeneities in magnetic and radiofrequency fields which
make signals on standard T1w images difficult to quantify (see
Supporting Information in File S1 for more detail). Such
measurements are independent of patient motivation and are
highly reproducible.
In this study both qualitative T1w imaging and quantitative fat
measurement, using the Dixon technique, together with functional
muscle assessment and strength tests, were acquired at baseline
and 12 months follow-up to detect the small pathological changes
expected. We present the results of the first longitudinal 12-month
natural history study of muscle fat content in a large multinational
cohort of LGMD2I patients. Muscle pathology progression over
12 months can be detected by quantitative MRI but not by
assessing muscle strength or function.
Materials and Methods
Setting and Study Population
This study complied with the Declaration of Helsinki, was
approved by local ethics committees and written informed consent
was obtained from each participant at the 4 centers: ethical
approval for the Newcastle upon Tyne and London centers was
provided by the Newcastle and North Tyneside Research Ethics
Committee 2 (reference 09/H0907/29); the Regional Committee
on Biomedical Ethics of Copenhagen (reference H-B-2009-061)
provided approval for the Copenhagen centre; and the Local
Ethics Committee CPP-Ile-de-France VI (reference 2009-A00808-
49) approved the Paris center. Thirty eight ambulant adults with a
genetically confirmed diagnosis of LGMD2I (19M:19F age 18–64
years, mean ages of 40.9 years and 40.0 years respectively and
disease duration 0–49 years) were recruited. Thirty two patients
(17M:15F age 19–65 years, mean ages of 40.3 years and 41.9
years) completed the follow up assessment after 12 months
including the MRI and the full standardized physical and
functional assessment: see Supporting Information in File S1 for
details of loss to follow-up. Inclusion criteria for the patients were:
identical genetic diagnosis with homozygous c.826C.A FKRP
mutations, ambulant for more than 50 metres, no ventilator
requirements and the ability to lie flat with no contraindications
for MRI scanning. Data were acquired locally at the four centers
between June 2009 and April 2011, using pre-agreed standardized
MRI and clinical and functional assessments with a standardized
reporting method.
A physiotherapy assessment was performed in all patients at the
time of the MRI. Strength testing of the lower limb on the
dominant side using a hand-held myometer (MicroFET) [14]
included knee extension, knee flexion, hip abduction and hip
adduction. Timed tests included a 10 metre walk/run [15], Timed
Up and Go test (TUG) [16] and a six minute walk distance
(6MWD) [17,18]. Forced vital capacity (FVC) was measured as the
best of three attempts using a hand-held spirometer, both sitting
and supine, and expressed as percentage of the expected value
based on height. Protocols and training manuals were produced
and teleconferences organised to ensure uniformity of approach.
MRI Acquisition
The acquisition protocol comprised (i) standard T1w imaging
allowing whole muscle qualitative evaluation and (ii) quantitative
fat imaging by the Dixon technique optimized for muscle fat-
fraction analysis: see Supporting Information in File S1 for further
detail on the method and advantages of Dixon imaging.
Acquisitions were performed at 3.0 T (Philips Achieva, Siemens
TIM Trio) with local surface-array receive coils for signal
detection. The use of different MRI scanners from different
vendors across the 4 participating sites necessitated detailed pre-
trial quality assurance activity using both water/fat phantoms and
healthy subjects to ensure quantitatively equivalent MRI results
across the centers (see File S1).
(i) T1w imaging. Axial T1w imaging was performed with a
turbo spin echo sequence (repetition time (TR)/echo time
(TE) = 671/10 ms, (Newcastle/Paris) or 16 ms (London), 12 ms
(Copenhagen), number of averages 2, acceleration factor 3, slice
thickness 5 mm, interslice gap 10 mm, 2566192 matrix interpo-
lated to 5126384). FOV 410 mm using multiple stacks to cover
both legs from the ankle to the pelvic crest.
(ii) Quantitative Dixon imaging. Spoiled gradient-echo
sequences were used in the axial plane. Protocol details varied
slightly between sites: Newcastle/London: 3 point Dixon images
acquired in 2D with TR/TE=100/3.45, 4.6, 5.75 ms, flip
angle = 10 degrees, 10 slices of 10 mm slice thickness, 5 mm
gap; Paris: 3D, 64 slices of 5 mm slice thickness with TR/
TE=10/2.75,3.95,5.15 ms, flip angle = 3 degrees; Copenhagen:
as per Paris, but with 36 slices per 3D acquisition, 2-point Dixon
with correction for B0 inhomogeneity [19]. Optimal TEs were
determined locally due to differences in the actual precise Bo
magnitude of Siemens and Philips scanners. Images were collected
at mid-lower leg and mid-thigh: the central plane of acquisition
was defined with respect to bone landmarks as follows: legs were
positioned with the patella anterior; the lower leg images were
centered by finding the broadest part of the lower leg muscle, and
recording the distance from the lower border of patella; thigh
images were centered by locating superior border of patella, and
the anterior superior iliac spine, with centering 1/3 of the distance
superior to the patella; the distances were recorded for prescription
of follow-up scans. Each leg was imaged individually using a
1606160 matrix interpolated to 2566256, FOV 2006200 mm: in
Paris, it was possible to scan both legs together at the same
resolution using FOV 4486244 mm. The data was analyzed off-
line to produce separate fat and water images [19,20] from which
quantitative fat-fraction maps were produced by expressing the fat
signal as a percentage of the total signal per voxel.
(iii) Interpretation. The images were analyzed by a
consultant neurologist (TW). The T1w images were assessed on
an individual muscle basis and graded according to the scale
published by Mercuri et al. [21,22] (Table 1), assessing 14 muscles
in the leg (9 in the thigh and 5 in the lower leg) and the gluteus
maximus muscle. The quantitative fat-fraction maps were
analyzed by defining regions of interest (ROIs) encompassing the
full cross-section of individual muscles on the separated water
image at the midpoint of both the lower leg and thigh for both
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baseline and follow-up datasets in 14 muscles, avoiding partial
volume effects at the boundaries. To assess the inter-observer
variability and hence objectivity of the measurements made, ROI
assessment of all muscles in the quantitative imaging and the
scoring of qualitative grades in a subset of 8 patients was also
performed by KGH, an MR physicist with 6 years’ experience of
muscle imaging. Bland-Altman analysis was performed to assess
the objectivity of the method for the quantitative images [23]. The
inter-observer Bland-Altman analysis gave an inter-observer bias
of 0.04% (no systematic bias) and an inter-observer repeatability
coefficient of 1.43% (95% of comparisons will fall within this
range). For the qualitative scoring, the two observers were in
agreement for 65% of muscle groups scored. Agreement was
highest at the extremes of the grades and least in the middle,
where only 39% agreement was achieved in scoring grade 2b.
Statistical Methods
The Shapiro-Wilk test demonstrated that the fat fraction
measurements were not normally distributed. The average fat
fractions in the group for a given muscle were therefore
characterised by the median, with minimum and maximum
values quoted. Non-parametric statistical tests were used for
analysis using the SPSS version 17.0 software (IBM, USA).
Comparison of fat-fraction changes between paired baseline and
follow up scans were tested using the Wilcoxon signed-rank test.
Comparison of the functional changes between baseline and follow
up were tested using the Wilcoxon signed-rank test. Statistical
significance was taken to be p,0.05.
Results
Analysis of T1w Images by Grading
Pelvis, thigh and lower leg T1w images were analyzed both at
baseline and at 12 months in the 32 patients for which MRI was
available at both time points. The biceps femoris short head
(BFSH) in 3 individuals could not be graded due to poor
visualisation of the muscle. Table 2 highlights that there is no
significant difference between the grades at baseline and follow-up
by scoring the muscles qualitatively. The majority of the muscles
remained the same grade at both baseline and follow up. Table S1
in File S1 shows the percentage of patients scoring grades 0–4 for
all 15 muscles on T1w MRI and the median grade scored in the 32
patients at follow-up.
For the gluteus maximus muscle 81% of the patients scored
grade 3 or 4 at baseline and follow up. Even in mildly affected
patients, the gluteus maximus muscle was often severely affected
early in the disease and did not appear to change longitudinally.
Quantitative Analysis – Dixon Technique
A total of 14 muscles per patient, nine muscles at mid thigh level
and five muscles at mid lower leg level, were analysed in all 32
patients at baseline and follow-up (Table 3). Gluteus maximus
muscle data was not acquired with the Dixon technique. The
distribution of muscle pathology was broadly similar at baseline
and follow-up and showed a broad spectrum of severity (Figure 1):
some muscles were more severely affected such as the biceps
femoris long head muscle (median fat fraction 71.6% at baseline),
whilst others demonstrated mild involvement, as in the tibialis
anterior muscle (median fat fraction 5.5% at baseline).
The fat-fractions in 9 out of the 14 muscles increased
significantly from baseline to follow-up, these being the medial
and lateral gastrocnemius muscle in the lower leg, and the
sartorius, gracilis, semimembranosus, semitendinosus, vastus
lateralis, rectus femoris and biceps femoris long head muscle in
the thigh. Changes in the fat fraction in other muscles did not
reach statistical significance over 12 months. Figure 2 illustrates
the difference in the fat fractions between baseline and follow-up
for each individual muscle, illustrating the spread of change in fat
fractions over the 12 months. There is wide variability of change in
the semimembranosus muscle and to a lesser extent in the biceps
femoris short head and semitendinosus muscles. This is possibly a
result of the heavy infiltration at baseline and hence difficulties in
ROI placements at follow up. While the biceps femoris short head
muscle was not heavily fat infiltrated, it was difficult to accurately
map the ROI between the initial and follow up scans, due to its
shape. Figures 3 and 4 show fat fraction maps from two individual
patients at baseline (a & c) and follow up (b & d). In Figure 3, the
most notable change over time occurred in the medial gastroc-
nemius muscle (fat fraction increased by 21%), with smaller
changes in the lateral gastrocnemius (4.6% increase), peroneus
longus (8.1%) and soleus (1.7%). The fat fractions in the vastus
lateralis and medialis also increased in this patient (7.0% and 7.2%
increase in fat fraction, respectively), with more modest increases
in the semimembranosus (4.7%), semitendinosus (4.4%), sartorius
(2.6%) and gracilis (2.3%). In Figure 4, there are marked increases
in the lateral and medial gastrocnemius (6.8% and 2.3% increase
respectively), and in the thigh, increases in sartorius, gracilis and
semitendinosus (4.5%, 4.5% and 4.7% respectively), with smaller
increases in the rectus femoris (1.5%) and vastus lateralis (1.3%).
Standardized Physical Testing
Over the 12 months period no significant changes were
detectable in the patients’ standardized physical test measurements
between baseline and follow-up (Table 4), despite evidence of
change in some individuals relating to timed tests and myometry
Table 1. Description of the qualitative muscle grading scale (21).
Grade Description
0 Normal appearance
1 Early moth-eaten appearance with scattered small areas of increased signal
2a Late moth-eaten appearance with numerous discrete areas of increased signal with beginning confluence, comprising less than 30% of the volume
of the individual muscle
2b Late moth-eaten appearance with numerous discrete areas of increased signal with beginning confluence, comprising 30–60% of the volume of the
individual muscle
3 Washed-out appearance, fuzzy appearance due to confluent areas of increased signal
4 End stage appearance, muscle replaced by increased density of connective tissue and fat, with only a rim of fascia and neurovascular tissue
distinguishable.
doi:10.1371/journal.pone.0070993.t001
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measurements, and a downward trend in all median measure-
ments except ankle dorsiflexion.
The timed tests for some individuals suggested an increase in
time to perform the stair climb, stair descend, 10 m walk, chair
rise, and TUG test. However, again the increase was not
significant for the group. The maximum value for the stair climb,
stair descend, chair rise and TUG used was infinity (‘) as some of
the patients were unable to perform this activity at follow up. The
median six minute walk distance appeared to even show an
improvement at follow up by 41 metres, but the change was not
Table 2. Median qualitative grades for selected muscles at baseline and at 12 months.
Muscle Baseline median grade 12 month median grade Number with same/increased/decreased grade P value
GM 4 4 25/4/3 .705
BFLH 4 4 29/1/2 .564
ST 3 4 23/4/5 .739
SM 3 3 20/5/7 .509
BFSH* 2b 2b 20/4/5 .739
SAR 2b 2b 19/8/5 .405
VM 2b 3 16/8/8 .819
GRAC 2a 2b 23/4/5 .739
VL 2b 2b 17/10/5 .346
RF 2a 2b 22/6/4 .527
MG 2b 2b 21/7/4 .218
LG 2b 2b 18/10/4 .073
PL 2b 2a 15/7/10 .655
SOL 2a 2b 23/5/4 .739
TA 2a 2a 26/3/3 .739
Number of patients with the same, an increased or decreased qualitative grade at the 12 months follow up compared to the baseline grade is given. Non-parametric
paired Wilcoxon signed rank test was used to assess change.
*BFSH was graded in 29 participants. BFSH in 3 subjects could not be graded due to poor visualisation. GM=Gluteus Maximus, BFLH= Biceps Femoris long head,
ST = Semitendinosus, SM= Semimembranosus, BFSH =Biceps Femoris short head, SAR = Sartorius, VM=Vastus Medialis, GRAC=Gracilis, VL = Vastus Lateralis,
RF = Rectus Femoris, MG=Medial Gastrocnemius, LG= Lateral Gastrocnemius, PL = Peroneus Longus, SOL = Soleus, TA = Tibialis Anterior.
doi:10.1371/journal.pone.0070993.t002
Table 3. Median values of the fat fractions at baseline and follow up.
Muscle Baseline min Baseline max Baseline median 12 month min 12 month max
12 month
median
Paired diff.
(sig)
BFLH1 1.5 97.3 71.6 2.2 94.4 75.2 0.004
ST1 2.3 100 55.7 2.1 96.1 59.7 0.021
SM1 2.6 94.1 49 2.9 95.6 54.2 0.015
BFSH 2.7 78.1 25.5 4.1 82.3 24.9 0.06
SAR1* 0.85 88.9 24.2 3.4 87.5 25.3 0.010
VM 1.1 89.1 25.6 0.8 83.5 30.9 0.065
GRAC1* 2.3 81.7 25.3 3.9 84.2 26.6 0.018
VL1* 0.6 82.1 15.6 1.2 82.1 20.9 0.025
RF1* 0.4 81.3 10.9 0.8 82.1 12.3 0.028
MG1* 1.1 90.3 21.7 1.3 90.3 22.6 0.009
LG1 0.8 88.4 19.3 0.8 87.8 23.9 0.009
PL 2.8 55 15.1 3.2 61.8 14 0.896
SOL 1.5 84.9 9.1 2.1 86 10.9 0.246
TA 1.4 24.6 5.5 1.3 23.5 5.2 0.627
The non-parametric paired Wilcoxon signed rank test was used to test significance.
1significant differences between baseline and 12 month follow-up.
*possible muscles for future longitudinal analysis; In lower leg; MG, In thigh; SAR, GRAC, VL and RF.
BFLH= Biceps Femoris long head, ST = Semitendinosus, SM= Semimembranosus, BFSH = Biceps Femoris short head, SAR = Sartorius, VM=Vastus Medialis,
GRAC=Gracilis, VL = Vastus Lateralis, RF = Rectus Femoris, MG=Medial Gastrocnemius, LG = Lateral Gastrocnemius, PL = Peroneus Longus, SOL = Soleus, TA = Tibialis
Anterior.
doi:10.1371/journal.pone.0070993.t003
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significant in the group. There were no significant correlations
between the changes in the timed tests across 12 months and the
changes in the muscle fat fractions measured by MRI.
The only statistically significant functional change over 12
months detected in our patient cohort was in forced vital capacity
(FVC). The FVC measurements were obtained from 25 patients at
baseline and follow up. The decrease in the FVC was significant
both when sitting (median 81% predicted to 76% predicted at 12
months, p = 0.001) and when lying (median 71% predicted to 66%
predicted, p = 0.02, Table 4).
Discussion
This is the largest reported MRI study (n= 32) of patients with
LGMD2I due to the common mutation in FKRP, and the first
longitudinal natural history study to use quantitative MRI in
LGMD2I. Quantitative fat imaging by the Dixon method
demonstrated significant increases in fat replacement in 9 muscles
across a 12 month period, while conventional physical testing of
the patients did not demonstrate significant differences: indeed the
median six minute walk distance appeared to increase, though not
significantly. Qualitative grading of T1-weighted MRI images by a
six-point scale was also shown to be insensitive. This study
demonstrates the power of quantitative MRI to provide reliable
objective outcome measures in a slowly progressing disease, as
would be required in a clinical trial of therapy. It also provides new
information about the rate of natural progression of pathology in
individual muscle groups.
In Table 3 we have highlighted potential target muscles for the
longitudinal assessment of pathological changes that were identi-
fied by our study. Targeting specific muscles for analysis in a
longitudinal trial would maximize the power of a large therapeutic
study. Muscles suitable for longitudinal analysis in LGMD2I were
the medial gastrocnemius muscle in the lower leg and the vastus
lateralis, gracilis and rectus femoris muscle in the thigh. These
were identified not only because of fat fraction progression over 12
months, but because they demonstrated a wide range of fat
fractions in patients at both the early and advanced stage of the
disease and the ROIs were easy to delineate on follow-up.
Unsuitable muscles included the tibialis anterior, which was only
mildly affected at baseline and did not progress, and the biceps
femoris long head which was already heavily fat-infiltrated at
baseline and therefore unlikely to respond to therapy. Consistently
well-positioned patients were essential for the delineation of
muscles and the ROI placements at follow-up to enable reliable
and uniform analysis of muscle pathology.
This work demonstrated that qualitative scoring of T1w images
was not discriminating enough to detect progression of muscle
pathology in patients with LGMD2I over a 12-month period,
compared to the quantitative fat imaging method, which
demonstrated significant increases in 9 out of the 14 muscles
analyzed. The qualitative scoring is subjective and there are
difficulties in assigning grades to some muscles due to the
imprecise boundaries of the scoring system, especially between
grades 2a, 2b and 3, leading to potential inconsistencies in scoring
Figure 1. Quantitative fat fraction images of the thigh in
LGMD2I patients showing the wide range of severity in fat
replacement at baseline, from minimal involvement (a) to
sparing of only gracilis and sartorius (e).
doi:10.1371/journal.pone.0070993.g001
Figure 2. Quantitative fat fraction differences from baseline to
12 month follow-up. The box indicates the lower and upper
quartiles, with the median change with time represented as the bar
within the box. The bars enclose the outliers.
doi:10.1371/journal.pone.0070993.g002
Figure 3. Quantitative fat fraction images at baseline in an
individual patient (a – mid lower leg level, c – mid thigh level)
and at 12 months follow-up (b – mid lower leg level, d – mid
thigh level). Analysis reveals an increase in fat fraction of the medial
and lateral gastrocnemius, peroneus longus, vastus lateralis and
medialis, semimembranosus, semitendinosus, sartorius and gracilis.
doi:10.1371/journal.pone.0070993.g003
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the T1w images. The interobserver repeatability of the T1w scores
showed that whilst there was overall agreement in the scoring of
the qualitative grades (65% of assessments), there was only 39%
agreement in scoring grade 2b. The quantitative analysis of the
images demonstrated good interobserver repeatability (inter-
observer coefficient 1.43%) and was an objective measure of fat
content in the individual muscles.
As shown in Table 4, the functional testing and physical
strength measurements did not show any significant difference
from baseline to follow up, apart from the FVC measurements:
while these measurements are clinically important, their relation-
ship to lower limb pathology is known to be indirect. The finding
of decreased FVC can have diagnostic value in distinguishing
LGMD2I patients from other LGMDs with normal respiratory
function: it is important that lung function is monitored in any
longitudinal trial, since respiratory care (including non-invasive
ventilation) is an important treatment approach for LGMD2I
patients. There were no significant correlations between the
change in FVC and the change in fat fraction of any muscle group.
Therefore, whilst functional assessments and strength tests are
important as they provide clinically relevant information on the
level of ability in these patients, objectively there was no statistical
difference detected over 12 months in the tests. The median six
minute walk distance, often used as the primary end-point of
clinical trials of therapy, actually appeared to increase after 12
months demonstrating its unsuitability for use in slow progressing
diseases. Learning effects from test repetition may affect these
types of measurement.
Future work could include both asymptomatic and paediatric
patients with the common FKRP mutation, in order to further
define the natural history of the disease. Limitations of the study
included the analysis of the quantitative Dixon scans at only one
level. Ideally, one would like to assess the ROIs at all levels of
potential target muscles and analyze the variability within muscles.
This may give further information regarding the process of muscle
damage occurring in this condition. In addition, while the
technique can assess the changes in fat and water composition of
the tissue, it cannot measure macromolecular species which may
not be MR-visible. This means that other pathological processes
which occur in LGMD2I, such as the development of fibrosis,
cannot be assessed by this technique.
Figure 4. Quantitative fat fraction images at baseline in an
individual patient (a – mid lower leg level, c – mid thigh level)
and at 12 months follow-up (b – mid lower leg level, d – mid
thigh level). Analysis reveals an increase in fat fraction of the lateral
and medial gastrocnemius, sartorius, gracilis, semitendinosus, rectus
femoris and vastus lateralis.
doi:10.1371/journal.pone.0070993.g004
Table 4. Minimum, maximum and median values of myometry, timed tests and FVC at baseline and follow-up in 32 paired
individuals.
Muscle Baseline min Baseline max
Baseline
median
12 months
min
12 months
max
12 months
median Difference (sig)
Hip Flex (pounds) 2.2 81.1 16.1 3.0 64.0 13.8 0.36
Hip Abd (pounds) 1.4 86.1 18.2 5.2 78.5 13.0 0.45
Hip Add (pounds) 1.6 58.9 14.1 4.0 74.8 9.1 0.11
Knee Flex (pounds) 1.9 66.1 18.6 0.0 70.5 17.7 0.10
Knee Ext (pounds) 4.3 156.6 26.3 4.4 142.3 20.5 0.82
Ankle DF (pounds) 5.6 86.3 38.0 4.0 93.6 46.0 0.16
Stair climb time (secs) 1.4 46.2 5.4 1.7 ‘ 6.4 0.08
Stair descend time (secs) 1.5 39.9 3.5 1.25 ‘ 4.5 0.24
Chair rise time (secs) 0.4 27.6 2.6 0.6 ‘ 3.3 0.55
TUG (secs) 4.3 50.5 12.0 4.1 ‘ 13.8 0.96
10 metre time (secs) 2.3 21.5 8.4 2.5 25.0 8.8 0.15
6MWD (metres) 67 625 312 50 718 353 0.77
FVC (sit) (% predicted)* 51 107 81 48 100 76 0.001
FVC (lie) (% predicted)* 36 105 71 28 100 66 0.02
Non-parametric paired Wilcoxon signed rank test was used. There was no significant difference found between the results at baseline and at follow up, apart from FVC.
‘ - the maximum time used for the analysis was infinity, to denote patients who were no longer able to do this test. Abd = abduction, Add = adduction, Flex = flexion,
Ext = extension, DF = dorsiflexion, TUG= timed up and Go, 6MWD= six minute walk distance, FVC = forced vital capacity.
*FVC data from 25 patients.
doi:10.1371/journal.pone.0070993.t004
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This study has shown that quantitative MR imaging by the
Dixon technique provides an objective measurement of the muscle
fat fraction that detects disease progression that cannot be
identified by conventional functional testing, including measures
such as the 6MWD presently used as primary trial end-points. In a
slowly progressing neuromuscular condition, such as LGMD2I,
quantitative MRI is able to demonstrate significant increases in
muscle pathology in 9/14 of the muscles studied. Quantitative
MRI could in the future be considered as a primary end-point of
choice in the longitudinal monitoring of these patients in clinical
trials.
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